Team Qld
Queensland, Australia's emerging Asia-Pacific biomedical hub
Australia’s $250-billion life sciences sector is one of the largest in the southern hemisphere and constantly growing. It’s home to more than 2,600 organisations. Our high-quality and innovative healthcare system is envied around the world and supports a world-class medical research sector.
Australia is one of the top 10 countries in the world for contributions to life sciences research and development. The Gardasil® human papillomavirus (HPV) vaccine for the prevention of cervical cancer was developed in Queensland, Australia.
The Australian Government provides support at each phase of the innovation pathway, including:
- The A$20 billion Medical Research Future Fund to address emerging health needs.
- The A$15 billion National Reconstruction Fund for manufacturing, with A$1.5 billion earmarked for medical manufacturing.
- The A$500 million Biomedical Translation Fund, which supports biomedical research commercialisation.
- A Research and Development Tax Incentive, which provides a tax offset of up to 43.5% on eligible R&D expenditure.
With a pro-business government; proximity to Asian economies; a well-educated and skilled workforce; and enviable liveability, Queensland is the perfect place to invest.
As Queensland prepares to welcome the world for the 2032 Olympic and Paralympic Games, it’s time for international investors to put themselves in a win–win position and choose Queensland as their preferred location.
Bright Minds. Bright Bio-future
Queensland is recognised as a leading biomedical industry hub for the Asia-Pacific region, offering globally recognised infrastructure for research, translation, manufacture and supply to the highest international standards.
The sector has the full backing of the Queensland Government through its Queensland Biomedical 10-Year Roadmap and Action Plan ( 605.5 KB), which sets out how we are going to grow, support and attract biomedical enterprises and invest in state-of-the-art facilities, talent and partnerships.
Our unique health and knowledge precincts combine hospitals delivering high-quality care, researchers conducting leading-edge research and innovative companies developing new products.
US medtech giant Stryker and global healthcare and pharmaceutical company Sanofi have chosen to establish a strong R&D presence in Queensland.
At the Translational Science Hub, Queensland’s world-class researchers connect with Sanofi scientists in France and the US, placing Queensland at the forefront of global mRNA vaccine development and biomedical research.
Fast facts on Queensland’s biomedical sector
-
$361m Private manufacturing R&D investment annually
-
$534.3m estimated export value
-
$2.1b+ economic contribution in gross value-added
-
Research-focused universities, with four in the world’s top 250
-
1 in 5 Australian clinical trials take place in Queensland
-
$1.3m low payroll tax (4.75%), high-exemption threshold
Clinical trials
Queensland is a global hub for cutting-edge clinical research and development, offering a one-stop shop for seamless end-to-end clinical trial solutions.
Innovation precincts
Queensland is home to some of the world’s most innovative entities. These organisations link our specialised infrastructure with universities, hospitals and research institutes, airports, ports, and industrial and manufacturing centres throughout the state.
World-class research
Queensland science makes a difference globally, with strengths across all the fields of science particularly in applying research to the real world.
“We have been seduced from day one by the quality of the science that we saw here, but also very much seduced by the ‘one Queensland team’ approach. We’re also coming here to Queensland because of the vision of the government of Queensland and the universities, working together with the ambition to make Queensland a global biomedical hub.”
Dr Jean-Francois Toussaint, Global Head of Vaccine Research and Development, Sanofi